Myelodysplastic Syndrome Drugs Market Report 2026

The myelodysplastic syndrome drugs market size has grown strongly in recent years. It will grow from $2.44 billion in 2025 to $2.66 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to limited availability of targeted mds therapies, reliance on blood transfusions, low awareness of mds subtypes, limited r&d investments, high treatment costs in emerging markets.

The myelodysplastic syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $3.84 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising incidence of mds due to aging populations, increased investment in precision medicine, advancements in genomics-based therapies, growing healthcare infrastructure in apac, expansion of reimbursement policies for mds drugs. Major trends in the forecast period include personalized mds therapies, increased adoption of erythropoiesis-stimulating agents (esas), expansion of outpatient treatment centers, growing preference for parenteral administration, rising focus on generic mds drug development.

The growing demand for personalized medicine is expected to drive the growth of the myelodysplastic syndrome drugs market in the coming years. Personalized medicine is a healthcare approach that categorizes patients into distinct groups based on factors such as medical history, genetic makeup, and molecular characteristics. In the context of myelodysplastic syndrome, personalized medicine focuses on customizing treatment strategies according to an individual’s specific genetic and molecular profile, which helps improve therapeutic effectiveness while reducing adverse effects in managing this complex hematological disorder. For example, in February 2024, according to the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, a notable increase from six approvals in 2022. Therefore, the rising emphasis on personalized medicine is driving the growth of the myelodysplastic syndrome drugs market.

Companies operating in the myelodysplastic syndrome drugs market are increasingly developing telomerase inhibitors that target the telomerase enzyme, with the goal of slowing disease progression by restricting the uncontrolled division of abnormal cells. Telomerase inhibitors are valuable in the treatment of myelodysplastic syndrome because they suppress telomerase activity, thereby limiting abnormal cell proliferation and potentially improving patient outcomes. For instance, in June 2024, Geron Corporation launched Rytelo (imetelstat), an FDA-approved intravenous telomerase inhibitor for adults with low- to intermediate-1-risk myelodysplastic syndromes who have transfusion-dependent anemia and are unresponsive to or ineligible for erythropoiesis-stimulating agents. Rytelo has demonstrated durable transfusion independence, improved hemoglobin levels, and addresses a significant unmet need in the myelodysplastic syndrome drugs market with a manageable safety profile.

In January 2023, Merck acquired Imago Biosciences, Inc. for an undisclosed amount. Through this acquisition, Merck seeks to strengthen its hematology portfolio by incorporating Imago Biosciences’ innovative therapeutic programs. Imago Biosciences specializes in developing novel treatments for hematologic malignancies, including myelodysplastic syndromes.

Major companies operating in the myelodysplastic syndrome drugs market are Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, AbbVie Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Teva Pharmaceutical Industries Ltd., Incyte Corporation, MEI Pharma Inc.

North America was the largest region in the Myelodysplastic syndrome drugs market in 2025. Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myelodysplastic syndrome drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the myelodysplastic syndrome drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and specialized biologics, particularly impacting segments like hypomethylating agents and erythropoiesis-stimulating agents. Regions such as North America and Europe, which rely on global supply chains for these drugs, have experienced supply delays and higher production costs. While tariffs pose challenges, they have also encouraged local manufacturing investments and regional supply chain diversification, potentially stabilizing long-term supply and reducing dependency on imports.

The myelodysplastic syndrome drugs market research report is one of a series of new reports that provides myelodysplastic syndrome drugs market statistics, including myelodysplastic syndrome drugs industry global market size, regional shares, competitors with a myelodysplastic syndrome drugs market share, detailed myelodysplastic syndrome drugs market segments, market trends and opportunities, and any further data you may need to thrive in the myelodysplastic syndrome drugs industry. This myelodysplastic syndrome drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myelodysplastic syndrome (MDS) is a group of disorders in which the bone marrow does not produce an adequate number of healthy blood cells, including red blood cells, white blood cells, and platelets, due to abnormal cell development and maturation. This condition arises from uncontrolled cell growth and division that leads to tissue damage. Drugs used in the treatment of myelodysplastic syndrome include epoetin alfa, darbepoetin alfa, filgrastim, and other MDS-related medications.

The main types of myelodysplastic syndrome drug therapeutics include immunomodulatory drugs, hypomethylating agents, and anti-anemic agents. Immunomodulatory drugs (IMiDs) are a class of medicines that regulate the immune system’s response and exert direct effects on bone marrow cells. The different types of syndromes include refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with excess blasts, and refractory anemia with ringed sideroblasts. These therapies are administered through various routes such as oral and parenteral administration and are used in both original and generic forms. They are utilized by several end users, including hospitals, clinics, and ambulatory surgical centers.

The myelodysplastic syndrome drug market consists of sales of drugs such as azacytidine, decitabine, and lenalidomide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.